Skip to main content
Equibles
SVRA logo

SVRA · Savara Inc

Track SVRA — free

Use SVRA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$5.46 +0.11 (+1.96%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.12B
Shares
205.46M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.35 Open$5.32 Day$5.29–5.41 52W close$3.31–6.94 Avg vol 30d1.7M Short int38.5M · 18.7% float · 27.1d Short vol62% Last earningsAug 6, 2020 DataJan 2020–Sep 2026 Filing10-Q · Aug 11

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1,000
Trailing 12 months
Net income (TTM)
−$139.31M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-19,182.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-9.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$142.93M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+17.2%
Year over year · more shares
Price change (1Y)
+63.1%
Trailing year
Short interest
18.7%
Latest settlement · 27.1 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 16.3 · calm Equity put/call 0.67
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −4%
below
Price vs 50-day avg −6%
below
RSI (14) 45
neutral
MACD trend Negative
52-week position 56%
mid-range
Momentum
relative strength
Very Weak
1-month return −1%
trailing
6-month return −3%
trailing
YTD return −11%
this year
Relative strength −16%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $6 › 200d $6 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +25 funds added
Insider flow Distributing
Net -$2.2M over 90 days · 100% sells
Short interest Rising
18.74% of float · ▲ +4.6% MoM · 27.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
183 holders — near 3-yr high, broad support
Squeeze score 71
high risk · 0–100
Fundamentals
Weak
Revenue growth −100%
Y/Y
EPS growth −10%
Y/Y
Free cash flow $-101.1M
Balance sheet $3.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 54%
annualized · 1-yr
Max drawdown −32%
past year
ATR 4.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−4% Neutral
Price vs 50-day avg
−6% Bearish
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
56% Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $6 › 200d $6 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +25 funds added
Insider flow Distributing
Net -$2.2M over 90 days · 100% sells
Short interest Rising
18.74% of float · ▲ +4.6% MoM · 27.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
183 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $5 · 56% Range high $7
vs 200-day avg -4% vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SVRA
Savara Inc
this stock
$1.12B -11.3% -100.0% — 18.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $140.51B +20.8% +46.2% 32.3 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $84.82B +6.7% +20.8% 20.4 2.3%
ARGX
Argenx SE
 $64.16B +22.3% — — 1.9%
MRNA
Moderna, Inc.
 $61.59B +423.1% +4.3% — 13.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
183
% held
105.8%
Net QoQ
+4.9M sh
Top holder
NEA Management Company, L…
Held Float
View
Held by Funds
Fund positions
130
View
Short & Settlement
Short Interest Rising
Shares short
38.5M
Days to cover
27.1d
Change
+1.7M sh
View
Short Volume
Short vol %
62%
As of
Sep 1, 2026
Short Total
View
Fails to Deliver
FTD shares
6.6K
Value
$34.7K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
35.6%
Week of
Jul 27, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$2.2M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$257.0K
Net income (FY)
$-118.8M
EPS diluted
$-0.53
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 11, 2026
This year
10
View
Proposed Sales
Value
$2.2M
Shares
394.5K
Filed
Jun 22, 2026
View
Exempt Offerings
Offering
$75.0M
Filed
Jan 2, 2020
View
Earnings & Events
Earnings Calls
Last call
Jun 3, 2026
View
Investor Relations
Latest news
Savara Announces Encore Presentat…
Published
Aug 24, 2026
View

Performance

5D 20D 120D MTD YTD
SVRA -4.5% -1.1% -3.3% -0.7% -11.3%
SPY -0.5% -1.2% +12.6% -0.7% +11.7%
vs SPY -3.9% +0.1% -15.9% -0.1% -23.0%
Key facts CIK 1160308 CUSIP 805111101 13F (30d) 164 filings 163 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)